Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
2 hedge funds and large institutions have $9K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
29% more capital invested
Capital invested by funds: $7K → $9K (+$2K)
33% less funds holding
Funds holding: 3 → 2 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.42K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $8K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1K | +$2.42K | +46,644 | New |
|
EYEGW Hedge Fund Activity: Q4 2018 in Review
2 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q4 2018, worth a combined $9K — up 29% from $7K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EYEGW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $2.42K.
- 2 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q4 2018, down from 3 in Q3 2018.
- Funds reported $9K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q4 2018, up 29% quarter-over-quarter.
- 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q4 2018 and 2 closed out, a net change of -1 holder.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q4 2018 was Susquehanna International Group, an estimated $2.42K added.
Based on aggregated 13F filings for Q4 2018.